Piper Sandler, Guggenheim and Truist acted as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
- Praxis Precision Medicines, Inc. Announces Proposed Public Offering
- Praxis Phase 2a results boosts credibility into readouts, says H.C. Wainwright
- Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
- Praxis Precision Medicines’ PRAX-628 shows high response in epilepsy study